Predictive Oncology Announces Closing of $4.1 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

The gross proceeds to the Company from this offering were approximately $4.1 million, before deducting the placement agents fees and other offering expenses payable by the Company.